Trial Profile
A Multi-Center Open Label Dose Escalation and Dose Expansion Study to Evaluate Safety, Tolerability, Dosimetry, and Preliminary Efficacy of the HER2 Directed Radioligand CAM-H2 in Patients With Advanced/Metastatic HER2-Positive Breast, Gastric, and GEJ Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 19 Jan 2024
Price :
$35
*
At a glance
- Drugs SGMIB anti-HER2 monoclonal antibody I-131 (Primary)
- Indications Advanced breast cancer; Brain metastases; Gastric cancer; Male breast cancer; Oesophageal cancer
- Focus Therapeutic Use
- Sponsors Precirix
- 12 Jan 2024 Planned End Date changed from 17 Jan 2025 to 31 Jan 2024.
- 12 Jan 2024 Status changed from recruiting to active, no longer recruiting.
- 06 Oct 2021 According to a PRECIRIX media release, the first has been dosed in the trial.